EMAIL THIS PAGE TO A FRIEND

Lancet (London, England)

Livebirth after uterus transplantation.


PMID 25301505

Abstract

Uterus transplantation is the first available treatment for absolute uterine infertility, which is caused by absence of the uterus or the presence of a non-functional uterus. Eleven human uterus transplantation attempts have been done worldwide but no livebirth has yet been reported. In 2013, a 35-year-old woman with congenital absence of the uterus (Rokitansky syndrome) underwent transplantation of the uterus in Sahlgrenska University Hospital, Gothenburg, Sweden. The uterus was donated from a living, 61-year-old, two-parous woman. In-vitro fertilisation treatment of the recipient and her partner had been done before transplantation, from which 11 embryos were cryopreserved. The recipient and the donor had essentially uneventful postoperative recoveries. The recipient's first menstruation occurred 43 days after transplantation and she continued to menstruate at regular intervals of between 26 and 36 days (median 32 days). 1 year after transplantation, the recipient underwent her first single embryo transfer, which resulted in pregnancy. She was then given triple immunosuppression (tacrolimus, azathioprine, and corticosteroids), which was continued throughout pregnancy. She had three episodes of mild rejection, one of which occurred during pregnancy. These episodes were all reversed by corticosteroid treatment. Fetal growth parameters and blood flows of the uterine arteries and umbilical cord were normal throughout pregnancy. The patient was admitted with pre-eclampsia at 31 full weeks and 5 days, and 16 h later a caesarean section was done because of abnormal cardiotocography. A male baby with a normal birthweight for gestational age (1775 g) and with APGAR scores 9, 9, 10 was born. We describe the first livebirth after uterus transplantation. This report is a proof-of-concept for uterus transplantation as a treatment for uterine factor infertility. Furthermore, the results show the feasibility of live uterus donation, even from a postmenopausal donor. Jane and Dan Olsson Foundation for Science.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

M0639
6α-Methylprednisolone, ≥98%
C22H30O5
46436
6α-Methylprednisolone, VETRANAL, analytical standard
C22H30O5
1046001
Azathioprine, United States Pharmacopeia (USP) Reference Standard
C9H7N7O2S
M1750000
Methylprednisolone, European Pharmacopoeia (EP) Reference Standard
C22H30O5
1435003
Methylprednisolone, United States Pharmacopeia (USP) Reference Standard
C22H30O5
Y0001602
Methylprednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard
C22H30O5
SML0284
Mycophenolate mofetil, ≥98% (HPLC)
C23H31NO7
1448956
Mycophenolate mofetil, United States Pharmacopeia (USP) Reference Standard
C23H31NO7
Y0000489
Mycophenolate mofetil, European Pharmacopoeia (EP) Reference Standard
C23H31NO7
PHR1451
Mycophenolate Mofetil, Pharmaceutical Secondary Standard; Certified Reference Material
C23H31NO7
Y0000519
Mycophenolate mofetil for peak identification, European Pharmacopoeia (EP) Reference Standard
C23H31NO7
P6004
Prednisolone, ≥99%
C21H28O5
46656
Prednisolone, VETRANAL, analytical standard
C21H28O5
PHR1043
Prednisolone, Pharmaceutical Secondary Standard; Certified Reference Material
C21H28O5
P2700000
Prednisolone, European Pharmacopoeia (EP) Reference Standard
C21H28O5
1555005
Prednisolone, United States Pharmacopeia (USP) Reference Standard
C21H28O5
BP464
Prednisolone, British Pharmacopoeia (BP) Assay Standard
C21H28O5
Y0001359
Prednisolone for peak identification, European Pharmacopoeia (EP) Reference Standard
C21H28O5
Y0001355
Prednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard
C21H28O5